CRA consultants assessed whether disputed representations of bioequivalence significantly affected sales of the branded product. The evaluation included consideration of distribution channels, purchase timing, and the effect of payor control mechanisms on product uptake and sales. The case ultimately resulted in a settlement.
How Views On US Healthcare Price Transparency Are Changing
Previously in a series of policy letters, Federal Trade Commission staff expressed concerns that transparency could lead to coordinated behavior and higher...